The results show that CDK12 amplification was found to be a potential predictor of trastuzumab response, and suggest HER2-positive breast cancer patients with simultaneous amplification of HER2 and CDK12 can benefit from CDK12 kinase inhibition (12). Here, ERBB2 is linked to breast carcinoma.